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Summary Somatostatin is a widely distributed inhibitory peptide with growth-inhibitory effects in several human tumours, including breast
cancer, raising the possibility that it may have therapeutic potential. The effects of somatostatin are mediated via a family of cell-surface
receptors that differ in their tissue distribution, pharmacological properties and intracellular response mediators, suggesting thatthey mediate
different functions of the peptide. We have analysed the expression of somatostatin receptor subtype (SSTR1-5) mRNA in normal and
malignant breast tissue. Receptor expression was analysed by reverse transcription-polymerase chain reaction (RT-PCR) using receptor
subtype-specific primers and by in situ hybridization (ISH) with riboprobes synthesized by in vitrotranscription of cloned PCR products. Atotal
of 51 breast carcinomas, 36 samples of matched normal tissue, two axillary node metastases and eight normal/benign breast tissue samples
were analysed. SSTR2 expression was ubiquitous in both normal and malignant breast tissue. Expression of SSTR5 was detected in
approximately one-third of tumour and normal tissue, but fewer than 13% of all tissues expressed SSTR1, 3 and 4. These data suggest that
SSTR2 gene expression is ubiquitous in breast cancer. Although this is unlikely to have diagnostic or prognostic significance, SSTR2-specific
somatostatin analogues may have therapeutic potential in breast cancer.
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Somatostatin is a widely distributed, multifunctional peptide
hormone that is unique in that its physiological actions are almost
universally inhibitory (Reichlin, 1983a,b). Negative growth-regu-
latory properties of somatostatin have been shown in a number
of human tumours, including breast cancer (Schally, 1988),
suggesting that it may have therapeutic potential in oncology. The
clinical use ofnative somatostatin, however, is limited by its short
half-life in the circulation and the broad spectrum ofits physiolog-
ical actions. These problems have beencircumvented by the devel-
opment of synthetic structural analogues of somatostatin with
enhanced selectivity and greater stability (Schally, 1988; Schally
et al, 1986). Growth inhibition by somatostatin and its analogues
occurs both indirectly, through the modulation of secretion of
trophic peptide hormones and growth factors, and directly via
interaction with tumour cells. There is also experimental evidence
that somatostatin inhibits angiogenesis, which is essential for
tumour development and growth (Woltering et al, 1990). At the
cellular level, the diverse physiological effects ofsomatostatin are
mediated via interaction with a family of specific cell-surface
receptors. Five distinct somatostatin receptor subtypes have been
identified, cloned, sequenced and partially characterized (Yamada
et al, 1992a,b, 1993; O'Carroll et al, 1994; Rohrer et al, 1993).
Although these receptors have a similar affinity for endogenous
somatostatin, their affinity for its structural analogues differs,
complicating the interpretation of receptor studies that have been
carried out using these analogues (Hoyer et al, 1994). However,
it appears that the five receptor subtypes have a distinct, but
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overlapping, tissue distribution, unique pharmacological proper-
ties and are coupled to a number of intracellular signalling path-
ways, suggesting that they mediate different functions of the
native peptide (Hofland et al, 1995). There is evidence that the
direct growth-inhibitory effects of somatostatin are mediated, at
least in part, by the activation of intracellular phosphatases
(Liebow et al, 1989), and receptor subtypes 1 and 2 have been
shown to be coupled to this intracellular pathway (Buscail et al,
1994-1995). However, growth inhibition has also been shown to
be mediated by receptor subtype 5 independently of intracellular
phosphatases (Buscail et al, 1995), suggesting that other pathways
are also involved in direct growth inhibition.
Somatostatin receptors have been demonstrated in up to 75% of
human primary breast cancers by biochemical cross-linking tech-
niques (Prevost et al, 1993), in vitro autoradiography (Papotti et al,
1989; Reubi and Torhorst, 1989; Reubi et al, 1990; van Eijck et al,
1994) and in vivo scintigraphy (van Eijck et al, 1994; Krenning et
al, 1993) using various synthetic analogues of somatostatin. No
study, however, has addressed the expression ofdifferent receptor
subtypes in breast tissue, knowledge of which is critical, if the
growth-inhibitory effects ofsomatostatin in breast cancer are to be
therapeutically exploited. In this study, we have analysed the
somatostatin receptor subtype expression in benign and malignant
breast tissue by reverse transcription-polymerase chain reaction
and in situ hybridization.
MATERIALS AND METHODS
Tissue collection
Fresh tissue samples were obtained from patients undergoing
surgery for breast disease. Tissues were dissected out, snap frozen
in liquid nitrogen for transport and subsequently stored at -80°C
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until analysed (0-12 months). The nature of all specimens was
confirmed histologically by a trained pathologist.
RNA extraction
Total cellular RNA was isolated from frozen tissue by
phenol-guanidinium extraction (Chomczynski and Sacchi, 1987)
using a commercially available kit (RNazol B, Biogenesis).
DNAase treatment RNA
Each of the five SSTR subtypes is encoded by an intronless gene.
As such, even minute amounts of genomic DNA contaminating
cDNA samples can be amplified by the sensitive technique of
PCR, producing a false-positive result. All RNA samples were,
therefore, treated with RNAase-free DNAase before reverse tran-
scription. Total RNA was incubated for I h at 37°C in a 50-,ul reac-
tion containing 40 mM Tris-HCl, pH 7.9, 10 mm sodium chloride,
6 mm magnesium chloride, 10 mm calcium chloride, 25 units
RNAase-free RQ1 DNAase and 40 units RNAase inhibitor (all
reagents from Promega). Following digestion of DNA, DNAase-
free RNA was extracted with phenol-chloroform, precipitated
with 100% ethanol and 2.5 M sodium acetate (pH 4) at -20°C
overnight and taken up in 50 jil of DEPC-treated, RNAase-free
water. The final concentration ofDNA-free RNA was determined
by absorbance at 260X (1 OD = 40 jig ml-') and solutions were
stored at -80°C.
Reverse transcription
A sample of5 jg oftotal DNA-free RNA was subjected to reverse
transcription using the Stratagene (RT-PCR kit). The completed
reaction products were stored at -20°C.
Polymerase chain reaction
Before analysis of SSTR expression, the presence of equal
amounts of amplifiable cDNA was confirmed for each reverse
transcription reaction by PCR using primers for the constitutively
expressed message P-actin (primers and conditions obtained from
Stratagene). All oligonucleotide primers for SSTR PCR reactions
were purchased from Cruachem Ltd., Glasgow, UK, and were
supplied and used as aqueous solutions without high-performance
liquid chromatography (HPLC) purification. Primer sequences for
each somatostatin receptor subtype were determined from the
Table 1 Upstream (PU) and downstream (PD) primer sequences for SSTR
1-5 PCR
Receptor Primer sequence Expected product
SSTR1 PU: 5'-TATCTGCCTGTGCTACGTGC-3' 217 bp
PD: 5'-GATGACCGACAGCTGACTCA-3'
SSTR2 PU: 5'-ATCTGGGGCTTGGTACACAG-3' 148 bp
PD: 5'-CTTCTTCCTCTTAGAGGAGCCC-3'
SSTR3 PU: 5'-TCAGTCACCAACGTCTACATCC-3' 188 bp
PD: 5'-ACGCTCATGACAGTCAGGC-3'
SSTR4 PU: 5'-CGCTCGGAGAAGAAAATCAC-3' 315 bp
PD: 5'-CCCACCTTTGCTCTTGAGAG-3'
SSTR5 PU: 5'-CGTCTTCATCATCTACACGG-3' 222 bp
PD: 5'-GGCCAGGTTGACGATGTTGA-3'
published cDNA sequences (Yamada et al, 1992a, 1993) using the
'Primer' software program (Version 0.5, Whitehead Institute for
Biomedical Research, Cambridge, MA, USA). The upstream
primer (PU) and downstream primer (PD) sequences for SSTR
1-5 are shown in Table 1.
Amplification of SSTR cDNA transcripts was performed in a
final volume of 25 jl, using as a substrate 5% (2.5 jl) of the
cDNA synthesized by reverse transcription of 5 jig of total RNA
as described above. All reagents were obtained from Promega.
Reactions were carried out in 1 x PCR buffer (50 mm potassium
chloride, 10 mM Tris-HCl, pH 9.0 at 25°C, 0.1% Triton X-100,
1.5 mm magnesium chloride in a final concentration of 800 jiM
dNTPs (200gM-each ofdATP, dCTP, dGTP and dTTP), 0.5 U Taq
polymerase and 1 jiM each primer. The optimized PCR conditions
were identical for each pair ofprimers except for the final concen-
tration ofdimethylsulphoxide (DMSO) which was 0% for SSTR2,
2% for SSTR1, 3 and 5, and 5% for SSTR4. Reactions were made
up to 25 jl with RNAase-free water, overlaid with 25 jl ofmineral
oil to prevent evaporation and subjected to amplification in a
Perkin Elmer DNA thermal cycler model 480. Amplification was
carried out for 35 cycles at 94°C for 30 s (denaturation), 60°C for
30 s (annealing) and 72°C for 30 s (extension).
Aliquots (10 jl) of each completed PCR reaction were resolved
on 2% agarose gels containing 0.5 jig ml-' ethidium bromide
together with DNA markers ofknown molecular weight visualized
under ultraviolet light and photographed.
Control experiments
For SSTR PCR, each sample was run with a negative control using
as a substrate DNAase-treated RNA, which was treated in parallel
with the test samples, but without addition ofthe reverse transcrip-
tase enzyme. For each batch ofPCR, a genomic DNA sample was
included as a positive control and a further tube without any
nucleic acid substrate was used as a negative control to exclude
contamination of reagents. For each cDNA, a minimum of two
independent PCRs was performed for each SSTR subtype.
Verification ofPCR products
Amplified PCR products were verified by (1) sequencing of
cloned PCR products; (2) Southern blotting and hybridization with
receptor subtype-specific probes.
Sequencing
PCR products were cloned into pGem-T (Promega), transformed
into competentE.colicells andcharacterized by dideoxy sequencing
using theT7 kitobtained fromPharmacia Biotech. Foreach receptor
subtype, the anticipated PCR product sequence was obtained.
Southern blotting
PCR products were transferred to nylon membranes by capillary
blotting and hybridization analysis was performed with cDNA
probes labelled to high specific activity with [ax2P]dCTP by
random priming ('Rediprime', Amersham, UK).
In situ hybridization
Hybridization was performed for SSTR2 and 5 on 7-jm cryostat
sections of tissue using riboprobes synthesized by in vitro tran-
scription of cloned PCR products labelled with digoxigenin (DIG
RNA Labelling Kit, Boehringer Mannheim Biochemica). Tissue
sections were flxed in 0.4% paraformaldehyde for 5 mmn and
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Table 2 SSTR 1-5 mRNA expression in human breast tissue as determined
by RT-PCR
Tissue analysed SSTR1 SSTR2 SSTR3 SSTR4 SSTR5
Tumour 2% 98% 8% 12% 35%
(n=51) (1) (50) (4) (6) (18)
Axillary node
metastases 50% 100% 0% 0% 0%
(n-=2) (1) (2) (0) (0) (0)
Matched
normal 8% 44% 0% 5.5% 5.5%
(n-36) (3) (16) (0) (2) (2)
Benign 12.5% 62.5% 0% 0% 37.5%
(n=8) (1) (5) (0) (0) (3)
Figure 1 RT-PCR (A) and Southern blot (B) analysis of SSTR5 mRNA
expression in primary breast cancers
A
B
Figure 2 Frozen sections of primary breast cancer following in situ
hybridization with antisense (A) and sense (B) riboprobes specific for SSTR2
hybridized overnight at 37°C in: 50% deionized formamide, 1 x
SPE (0.05 M Tris-HCl, pH 7.5; 0.1% sodium hydrogen phosphate;
0.2% polyvinylpyrrolidone (mol. wt. 40 000); 0.2% Ficoll (mol.
wt. 400 000) 5 mM EDTA), 10% dextran sulphate, 0.5 mg ml-'
tRNA, IM sodium chloride and 150 ng ml-1 riboprobe (reagents
obtained fron Sigma). Non-hybridized probe was washed off with
1 x saline sodium citrate (SSC), followed by 30% formamide in 1
x SSC. Hybridized probe was visualized by anti-digoxigenin anti-
body conjugated to an alkaline phosphatase detection system
(Boehringer Mannheim Biochemica). For each sample, a control
reaction was carried out on an adjacent tissue section using a sense
probe. A further negative control for each probe was carried out on
tissue sections pretreated with RNAase. Hybridized sections were
mounted in crystal mount, visualized by light microscopy and
photographed.
RESULTS
Amplifiable cDNA, as determined by the ability to amplify -
actin, was obtained from 51 primary breast cancers, 36 samples of
matched normal breast tissue (histologically normal tissue taken
from the same breast as tumour), two axillary node metastases and
eight samples ofbenign breast tissue.
Patient details
Clinical and pathological data were available for 49 of the 51
women with breast cancer.
Menopausal status
Altogether, 77.5% of women were post-menopausal (>6 months
since last menstrual period).
Staging
The majority oftumours were T1 (37%) orT2 (41%), 6% were T3,
12% T4 and 4% of cases were pure in situ disease; 49% ofpatients
were axillary node positive, but none had clinical evidence of
distant metastases.
Histology
Most tumours were invasive ductal carcinomas (86%), 10% were
of special histological type (tubular, cribriform, colloid or classic
lobular) and 4% were pure ductal carcinoma in situ (DCIS).
Grade
Over half (55%) of the invasive tumours were poorly differenti-
ated (Bloom and Richardson grade 3), 28% were grade 2 and 17%
grade 1.
Oestrogen receptor status (ER)
Of 39 tumours for which ER status was available, 25 (64%) were
ER positive.
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SSTR mRNA expression
Expression ofmRNA for each ofthe SSTR subtypes was analysed
by RT-PCR. Following PCR and resolution on agarose gels, prod-
ucts of amplification were transferred to nylon membranes and
hybridized with a32P-labelled type-specific cDNA probes. The
results of one such analysis for somatostatin receptor subtype 5
expression are shown in Figure 1. Table 2 summarizes the mRNA
expression of the five SSTR subtypes in the tissues studied as
determined by RT-PCR. SSTR2 was expressed in all but one of
the tumours analysed (98%), 44% of matched normal tissue and
62.5% of benign breast tissue. SSTR5 was the next most
commonly expressed receptor in tumours (36%). Two of 36
(5.5%) samples of matched normal tissue and three of eight
(37.5%) benign tissues expressed this receptor. The remaining
three receptor subtypes, SSTR1, 3 and 4, were expressed in less
than 13% of cases in all of the tissues analysed. Receptor subtype
expression in the two nodal metastases was identical to that of the
primary tumours from which they were derived. All but one ofthe
tumours analysed and 50% ofmatched normal tissues expressed at
least one receptor subtype (SSTR2 in virtually all cases). In all,
39% of tumours (all invasive ductal carcinomas) expressed more
than one receptor subtype, and tumours of special histological type
expressed only SSTR2. Whereas the four tumours that expressed
SSTR3 were grade 3, the other receptor subtypes were expressed
by all histological grades of tumour and by normal tissues. No
tissues expressed all five receptor subtypes. There was no statisti-
cally significant correlation between receptor subtype expression
and any of the clinical or pathological data mentioned above.
In situ hybridization
To localize expression of somatostatin receptor subtypes 2 and 5,
in situ hybridization was performed on frozen tissue sections.
Serial cryostat sections of tumour containing both benign and
malignant epithelial cells (as determined by haematoxylin and
eosin staining) were selected for hybridization with riboprobes
specific for SSTR2 and 5.
SSTR2
Fourteen tumours and one benign tissue sample were analysed
for SSTR2 expression by ISH. Clear cytoplasmic staining was
detected in both benign and malignant epithelial cells in all 15
cases. These findings correlated with the results ofRT-PCR for all
but one ofthe tumours, which was negative on RT-PCR, but posi-
tive on ISH. Matched normal tissue had been analysed by RT-PCR
foronly three ofthese 14 tumours and all had been SSTR2 positive.
An example ofthe results ofISH for SSTR2 is shown in Figure 2.
SSTR5
Ten tumours and one benigntissue section were analysed forSSTR5
expression by ISH. Cytoplasmic staining of normal and malignant
epithelial cells was demonstrated in seven tumours, one of which
had been negative on RT-PCR. In addition, one tumour that had
been positive on RT-PCR was negative on ISH. The section of
normal breast tissue was positive on both RT-PCR and ISH.
DISCUSSION
In this study, we have determined the somatostatin receptor
subtype expression in benign and malignant human breast tissue
by RT-PCR and ISH. Lack of reliably specific receptor subtype
analogues and monoclonal antibodies precludes the detection of
receptors at the cell surface and we therefore elected to analyse the
steady-state levels of messenger RNA for each receptor subtype.
RT-PCR was chosen because it is an exquisitely sensitive tech-
nique that will amplify small quantities of messenger RNA, and in
many cases only small amounts of tissue were available for
analysis. ISH is less sensitive, but allows nucleic acids to be visu-
alized in their cellular environment and was used to localize
mRNA expression in the tissues studied.
The most striking observation from this study is that SSTR2 is
ubiquitously expressed in breast cancer. Only one tumour out of51
was SSTR2 negative on RT-PCR, and expression was subse-
quently detected in this tumour by ISH. This finding is in agree-
ment with previous studies, which have shown that SSTR2 is
commonly expressed in human tumours (Eden and Taylor, 1993;
Reubi et al, 1994). SSTR2 expression was detected less often in
normal breast tissue by RT-PCR (44% matched normal, 62.5%
benign/normal), but ISH revealed that histologically normal breast
epithelial cells also universally express SSTR2. The apparent
lower sensitivity of RT-PCR compared with ISH probably results
from the relative paucity of epithelial cells in normal breast tissue
compared with tumour. Virtually all the women from whom
matched normal tissue was obtained in this study were peri- or
post-menopausal (mean age, 60 years; range 42-79 years), an age
at which the breast consists primarily of fat with little epithelial
tissue identifiable histologically. In fact, matched normal tissue
was only available for analysis in 36 of 51 cancer patients because
tissue samples from the remaining 15 patients were found to
contain no normal epithelial tissue. The benign/normal tissues
were obtained from a younger age group (mean age, 45 years;
range 26-60 years) undergoing surgery for benign breast disease.
In this younger age group, epithelial tissue may have been more
abundant, and 62.5% of these tissues were SSTR2 positive. Tissue
sections used for ISH were selected for their high content of
both benign and malignant epithelium, and the sensitivity of PCR
could similarly be improved by microdissection of tissue samples
before analysis. A similar pattern of expression was seen for
SSTR5, which was the next most commonly expressed mRNA.
Approximately one-third of tumours and benign/normal breast
tissue expressed this gene, as determined by RT-PCR, compared
with only 5.5% of matched normal tissue, suggesting that expres-
sion of SSTR5 may be more tumour-specific than SSTR2.
However, ISH again demonstrated that when SSTR5 was
expressed by tumours, it was also expressed by normal tissue
within the same tissue section, suggesting that RT-PCR has under-
estimated the expression of SSTR5 mRNA in matched normal
tissue. The results of ISH indicate that tumours arising in breast
tissue expressing SSTR5 mRNA retain this expression, and those
arising in SSTR5-negative breast tissue remain SSTR5-negative.
SSTR5 is the most recently described of the five SSTRs and, as
such, little work has previously been reported on its expression for
comparison with these results.
There was good correlation overall between the results for ISH
and those for RT-PCR for both SSTR2 and SSTR5. For ISH, all
positive cases demonstrated cytoplasmic staining in both normal
and malignant epithelial cells, although in some cases staining was
heterogeneous. This is most likely to represent artefact, but would
be consistent with the results of some affinity binding studies,
which have demonstrated heterogeneous distribution of somato-
statin receptors (Reubi et al, 1990; Papotti et al, 1989).
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The remaining three receptor subtypes (SSTR1, SSTR3 and
SSTR4) were expressed infrequently in both tumour and normal
tissue, and ISH was not carried out for these receptors. Previous
studies have shown that these receptors are less commonly
expressed than SSTR2 and are seen mainly in endocrine and
gastrointestinal tumours (Eden and Taylor, 1993; Reubi et al, 1994).
The results of this study must be interpreted with caution
because the detection of gene expression, as determined by the
presence ofmRNA, does not necessarily imply the expression ofa
functional cell-surface receptor. However, it has been shown that
the detection of SSTR mRNA by ISH correlates well with cell
surface receptor detection by in vitro binding with native somato-
statin and its analogues (Reubi et al, 1994).
The data presented in this study are particularly relevant to the
application of currently available somatostatin analogues to the
treatment of breast cancer, a disease which causes 16 000 deaths
per year in the UK. Both direct and indirect growth-inhibitory
effects of somatostatin and its analogues have been demonstrated
in breast cancer on cell lines in vitro (Setyono-Han et al, 1987;
Scambia et al, 1988) and tumour xenografts in vivo (Weber et al,
1989; Noguchi et al, 1993). Indirect growth inhibition is likely to
be secondary to a decrease in systemic and local levels ofpeptides
known to be trophic for breast cancer cells, such as growth
hormone (Rose et al, 1983) and its mediator insulin growth factor
1 (IGF-1) (Pollack et al, 1989), insulin (Furlanetto and DiCarlo,
1984) and epidermal growth factor (EGF) (Ghirlanda et al, 1983).
In this respect, the effects of somatostatin and its analogues have
been shown to be synergistic with LHRH agonists (Szende et al,
1989) and tamoxifen (Huynh and Pollack, 1994; Weckbecker et al,
1994). Direct growth-inhibitory effects are mediated via specific
high-affinity tumour cell surface receptors, but it is unclear at
present which of the five receptor subtypes so far identified are
responsible for this effect and which intracellular pathway is
involved.
The five SSTRs are G-protein-coupled receptors (GPRs) that
exhibit 40-60% overall sequence homology (Yamada et al, 1993).
They have a similar affinity for endogenous somatostatin and are
all coupled via pertussis toxin-sensitive G-proteins to adenylate
cyclase (Patel et al, 1994). However, there are important differ-
ences between the receptor subtypes, which suggest that they may
mediate different functions of the native peptide. Each receptor
subtype has a distinct tissue distribution, different ligand specifici-
ties and is linked to different intracellular coupling systems in
addition to adenyl cyclase (reviewed in Hofland et al, 1995).
Structurally, the greatest homology is between SSTR2, SSTR3 and
SSTR5 on the one hand and SSTR1 and SSTR4 on the other, and
these structural homologies translate into similar pharmacological
profiles (Serrano et al, 1993). The three analogues of somatostatin
that are currently in clinical use, octreotide, RC-160 and BIM-
23014 (lanreotide), bind with high affinity to SSTR2, SSTR5 and
with moderate affinity to SSTR3, but have very low affinity for
SSTR1 and SSTR4 (Hoyer et al, 1994).
There is experimental evidence that the direct growth-inhibitory
effects of somatostatin are mediated via receptor subtypes 1, 2 and
5. Buscail et al (1995) demonstrated that ofthe five SSTR subtypes,
only SSTR2 and SSTR5 produced growth inhibition in CHO cells,
but by different mechanisms, SSTR2 acting via the stimulation of
tyrosine phosphatases and SSTR5 via the inhibition ofintracellular
calcium mobilization. SSTR1 has also been shown to mediate
growth inhibition through tyrosine phosphatases, but in different
cell lines (COS-7 and NIH 3T3 cells) (Buscail et al, 1994).
In summary, there is a considerable body of experimental
evidence to suggest that somatostatin analogues have growth-
inhibitory effects in cancer. Indirect growth inhibition is likely to
be non-specific, but evidence suggests that direct growth inhibi-
tion will be most effective in those tumours that express somato-
statin receptor subtypes 1, 2 or 5. In this study, we have
demonstrated that two of the SSTRs that mediate direct growth
inhibition are expressed in breast cancer. SSTR2 is expressed in all
tumours and SSTR5 is expressed in approximately one-third of
tumours. Structural analogues of somatostatin with high affinity
for both of these receptor subtypes are already available and in
safe clinical use, and these analogues may therefore have a signif-
icant role in the management ofbreast cancer.
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NOTE ADDED IN PROOF
Our preferred primers for SSTR3 are now, forward, 5'-ggCCC-
TCCCgCCgTgT-3' and reverse, 5'-CgCTCCTgCCCgCTggT-3'.
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